Work

Delayed Signs of Early Disability Progression After 8.5 Years of Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis (S46.003)

Year: 2023

Type: article

Abstract: To assess the efficacy of earlier initiation of ocrelizumab on reaching key disability milestones, after 8.5 years of follow-up in the double-blind period (DBP) and open-label extension (OLE) of the pooled OPERA I/II (NCT01247324/NCT01412333) studies in patients with relapsing multiple sclerosis.

Source: Neurology

DOI: 10.1212/wnl.0000000000202203

Authors: Martin Weber, Ludwig Kappos, Stephen Hauser, Hans-Martin Schneble, Qing Wang, Gavin Giovannoni

Institutions: Fraunhofer Institute for Translational Medicine and Pharmacology, Universitätsmedizin Göttingen, University of Basel, University Hospital of Basel, University of California, San Francisco, F. Hoffmann-La Roche AG, Queen Mary University of London

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4367304967

FWCI: 0.189

Cites:

Cited by: 1

Related to: 10